Untitled

Abouelenein, Rasha Kamal; Refaie, Ayman Fathi; Alhendy, Yaser A; Okily, Amir Mohamed Al; Elserwy, Nabil Abdelfadil; Mashaly, Mohamed Elsayed; Abbas, Mohamed Hamed; Bakr, Mohamed A.

doi:10.6002/ect.2017.0301

Cited by 3 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,25,28 The wide variability in the frequency of PTE may result from different definitions of PTE in different studies, different inclusion criteria, different hematocrit cutoffs between male and women, and different requirements for a minimum duration of PTE. 6,29,30 In our study, we defined PTE for all patients with hematocrit greater than 51% and/or hemoglobin above 17 g/dL as was defined by most studies.…”

Section: Discussionmentioning

confidence: 99%

Post‐transplantation erythrocytosis in kidney transplant recipients—A retrospective cohort study

Hofstetter

Rozen‐Zvi

Schechter

et al. 2021

European J of Haematology

View full text Add to dashboard Cite

Post-transplant erythrocytosis (PTE) is commonly defined as an elevated hematocrit that appears after kidney transplantation, 1,2 rising to a level greater than 51% with a hemoglobin level greater than 17 g/dL. The prevalence of PTE is estimated to be 8%-15% 3 of kidney transplant recipients although higher rates have also been described. 4,5 PTE usually occurs within the first two years after the transplantation 5 with a variable onset reported from 3 to 90 months post-transplant. 2 Spontaneous remission of erythrocytosis is observed in one fourth of patients within two years of onset. 1A number of factors predisposing to PTE have been identified including male gender, preserved glomerular filtration rate (GFR), rejection-free course, and retained native kidneys. 1,5 Duration of

show abstract

Section: Discussionmentioning

confidence: 99%

Post‐transplantation erythrocytosis in kidney transplant recipients—A retrospective cohort study

Hofstetter

Rozen‐Zvi

Schechter

et al. 2021

European J of Haematology

View full text Add to dashboard Cite

show abstract

Risk Factors for Erythrocytosis in Renal Transplantation: Is Ganciclovir Therapy One of Them?

Koçak

Bali

2022

Ann Transplant

View full text Add to dashboard Cite

Background The purpose of this study was to identify the prevalence and risk factors of post-transplant erythrocytosis (PTE) and its relationship with cytomegalovirus (CMV). Material/Methods The study consisted of patients who received a kidney allograft and followed-up in our nephrology transplantation clinic from 2000 to 2014. Patient age, sex, length of dialysis, etiology of end-stage kidney disease, date of transplantation, medications, types of donors, the development of PTE were recorded. Results Among 185 adult kidney recipients, 43 (23.2%) had PTE. The average time between transplantation and diagnosis was 36 months. PTE was more common in male patients ( P <0.05) and patients with living donors and those who had been treated with ganciclovir after transplantation ( P <0.05). There were 79 patients treated for CMV – 54 in the non-PTE group and 24 in the PTE group. There was no significant difference in patient age, etiology of end-stage kidney disease, and immunosuppressive therapy when comparing the PTE group and non-PTE group. Univariate analysis showed ganciclovir therapy was significantly associated with PTE. However, this was not seen in the multivariate analyses. Conclusions Treatment with ganciclovir can precipitate development of PTE. Prospective studies are needed to assess the association of between PTE and CMV infection, valganciclovir, and ganciclovir.

show abstract

Absence of Polycythemia Vera in Postrenal Transplant Erythrocytosis

Langabeer¹

2020

Exp Clin Transplant

View full text Add to dashboard Cite

Untitled

Cited by 3 publications

References 15 publications

Post‐transplantation erythrocytosis in kidney transplant recipients—A retrospective cohort study

Post‐transplantation erythrocytosis in kidney transplant recipients—A retrospective cohort study

Risk Factors for Erythrocytosis in Renal Transplantation: Is Ganciclovir Therapy One of Them?

Absence of Polycythemia Vera in Postrenal Transplant Erythrocytosis

Contact Info

Product

Resources

About